Elicera Therapeutics AB ’s Post

In this MEDtalk, Professor of Gastrointestinal Oncology Jaffer A. Ajani, MD Anderson Cancer Center, USA, presents the most recent efficacy and safety findings from the phase III SPOTLIGHT study. This study evaluates the use of zolbetuximab in conjunction with mFOLFOX6 as a first-line treatment option for patients diagnosed with claudin-18 isoform 2-positive (CLDN18.2+), HER2-negative, locally advanced (LA) unresectable, or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. When combined with the results from the GLOW study, it becomes evident that claudin-18.2 has emerged as a new biomarker, not only in gastric cancer but also in oncology, presenting a legitimate new target for cancer treatment that holds great promise for the benefit of patients. #ESMO23 #Study 

Groundbreaking results from GSK as a Phase II trial have steered in what could be a transformative era for rectal cancer treatment. The novel antibody therapy, Jemperli, has achieved a staggering 100% clinical complete response rate in first-line therapy for patients with advanced rectal cancer 👏 This breakthrough is a sign of promise for those affected by mismatch repair deficient (dMMR) rectal cancer. The longevity of tumour regression observed in this trial - with a median follow-up of 26.3 months - is particularly promising. It signals a potential paradigm shift from traditional invasive treatments to a non-surgical approach that could preserve quality of life 🌟 Jemperli's safety profile is a further win, with no severe adverse events reported in the trial, aligning with the treatment's known tolerability and with Jemperli's EU approval for certain endometrial cancers, we're witnessing the unfolding of an exciting chapter in oncology 😊 #GSK #AnaptysBio #CancerTreatment #RectalCancer #OncologyInnovation #ClinicalResearch #Clinicaltrials #LifeScience #ElixirAssociates #StaffingPartner

Moderna, attacking Lung Cancer!! RAHWAY, N.J. & CAMBRIDGE, M.A., Dec. 11, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment in patients with completely resected (R0) Stage II, IIIA or IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.

Tumor necrosis factors (TNFs) and their receptors (TNFRs) are important regulators of the immune system. The dysregulation of TNFs/TNFRs is associated with tumorigenesis, progression, invasion, and metastasis. Targeting TNFs/TNFRs for cancer immunotherapy has sparked significant interest in recent years. As of January 2024, the FDA has approved five drugs targeting BCMA for myeloma. An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to specifically target Hodgkin's lymphoma and mesenchymal large cell lymphoma. Other popular targets for TNFs include RANKL, TRAIL, BLys, and CD40L, as well as TNFRs, like 4-1BB, Fas/CD95, and GITR. Browse our comprehensive catalog of recombinant TNF and TNFR proteins and corresponding antibodies: https://ow.ly/X7IT50QAEsU. #CancerImmunotherapy #TNF #TargetedTherapy

New clinical and biomarker data supporting CAN-2409 experimental treatment to improve survival in solid tumors: Candel Therapeutics announces positive interim data from randomized phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The primary endpoint in this clinical trial is the gold standard endpoint in pancreatic cancer: overall survival. This is what matters to patients and regulators. Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm after SOC chemoradiation. Median overall survival has not yet been reached in patients who received CAN-2409 because 5 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with two patients surviving more than 45 months from enrollment. #sitc2023 abstract 653 #viral #immunotherapy #cancer #pancreaticcancer #solid #tumor #CandelTherapeutics $CADL

Our poster at the AACR Annual Meeting is your chance to explore advances in novel cancer therapy combinations alongside MetrumRG modeling and simulation innovators. QSP model simulations were used to predict anti-tumor efficacy and guide dosing of the antibody-drug conjugate Loncastuximab tesirine combined with T cell-dependent bispecific antibodies, Mosunetuzumab or Glofitamab for the treatment of B-cell malignancies. Targeted Treatments: Lonca targets CD19 on B cells, while Mosun and Glofit redirect T cells to malignant B-cell by simultaneously engaging CD20 on B cells and CD3 on  T cells. Researchers: Yuezhe Li, A Katharina Wilkins, and Tim Knab from MetrumRG, along with J.P. Boni from ADC Therapeutics, conducted this innovative research. Model Predictions: Learn how our PKPD QSP model, presented by Katharina Wilkins, forecasts improved tumor growth inhibition with Lonca + Mosun/Glofit combination therapy compared to either monotherapy. Clinical Insights: Explore how these findings can impact treatment strategies for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in ongoing clinical trials. Date: Sunday, April 7, 2024 Time: 1:30 PM - 5:00 PM Location: Poster Section 36 Abstract Number: 19 #AACR2024 #CancerTherapy #CombinationTherapy #AACRAnnualMeeting #PosterSession #QSP

Our poster at the AACR Annual Meeting is your chance to explore advances in novel cancer therapy combinations alongside MetrumRG modeling and simulation innovators. QSP model simulations were used to predict anti-tumor efficacy and guide dosing of the antibody-drug conjugate Loncastuximab tesirine combined with T cell-dependent bispecific antibodies, Mosunetuzumab or Glofitamab for the treatment of B-cell malignancies. Targeted Treatments: Lonca targets CD19 on B cells, while Mosun and Glofit redirect T cells to malignant B-cell by simultaneously engaging CD20 on B cells and CD3 on  T cells. Researchers: Yuezhe Li, A Katharina Wilkins, and Tim Knab from MetrumRG, along with J.P. Boni from ADC Therapeutics, conducted this innovative research. Model Predictions: Learn how our PKPD QSP model, presented by Katharina Wilkins, forecasts improved tumor growth inhibition with Lonca + Mosun/Glofit combination therapy compared to either monotherapy. Clinical Insights: Explore how these findings can impact treatment strategies for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in ongoing clinical trials. Date: Sunday, April 7, 2024 Time: 1:30 PM - 5:00 PM Location: Poster Section 36 Abstract Number: 19 #AACR2024 #CancerTherapy #CombinationTherapy #AACRAnnualMeeting #PosterSession #QSP

Voltron Therapeutics is reshaping cancer therapy with its state-of-the-art Self-Assembling Vaccine (SAV) platform. Recent highlights from an Investor Event revealed promising results from drug candidate VTX-067, showing effectiveness against HPV-driven cancers through robust immune activation, enhanced survival rates, and reduced tumor sizes. Additionally, VTX-0P4 displays promise in treating prostate, bladder, and kidney cancers. The SAV platform's exceptional tumor-targeting abilities, highlighted by strong pre-clinical data, suggest potential for novel drug combinations, particularly with PD-1 agents. A transformative era in cancer treatment is upon us.

What will be some of the big talking points and clinical data relevant to large pharma at ASCO 2024? Bloomberg's May 28th ASCO preview will cover: >> Dual checkpoint data from Bristol-Myers Squibb that could upend the first line standard of care in MSI-H colorectal cancer and hepatocellular carcionma >> ADC mania, with new or updated results from AstraZeneca and Merck for the red-hot therapy class in lung and breast cancer and DLBCL, as well as closely watched details on GlaxoSmithKline's efforts to resurrect Blenrep after withdrawing it from the market in 2022 >> Late breaking results due from the second ever controlled and first phase III study testing neodjuvant therapy in melanoma, as well as the latest update on Moderna's personalized mRNA cancer therapy Register here: https://lnkd.in/eXJx_BgK #corporations #oncology #data #ASCO24

Its been a busy summer for #GelCount studies. Notably, among them is a study led by a distinguished team from the University of Liverpool. This study focused on the evaluation of various combinational treatments against castration-resistant prostate cancer. The findings of the preprint are particularly promising as the team identified several synergistic combinations that exhibited a significant reduction in cellular prostate growth. These promising results pave the way for potential investigation and exploration of new potential #cancer therapies in future studies. The #GelCount platform's contribution to this research showcases its importance as a valuable tool in advancing cancer research and its potential to help improve future patient outcomes. We look forward to further advancements and discoveries in this crucial field, which may ultimately lead to more effective treatments for prostate cancer and other malignancies. #ProstateCancer #invitro #SoftAgarAssay #oncologyresearch #cancertherapy